ctDNA-guided Adjuvant Chemotherapy in Liver Metastasis of Colorectal Cancer

Korábbi kezelés

• Patients who have received other tumor-related investigational drug therapy;
• Patients with severe uncontrolled recurrent infections or other serious uncontrolled concurrent diseases;

Más betegség

• Patients with a history of other malignancies;
• Patients with severe liver, kidney, heart and lung dysfunction, coagulation dysfunction, or serious underlying diseases who cannot tolerate chemotherapy;
• Patients who are allergic to any component in the study;
• Patients with a history of severe mental illness;

Laborértékek

• Patients with other factors that may affect the study results or lead to premature termination of the study, such as alcoholism, drug abuse, other serious diseases that require comprehensive treatment (including mental disorders), and serious abnormal laboratory tests;
• Patients with other clinical or laboratory conditions that the investigator deems unsuitable for participation in the trial.

Egyéb

• Patients with distant metastases, including pelvic, ovarian, peritoneal, etc.;
• Pregnant or lactating women;

• Both genders are eligible; aged between 18-75 years old; have received neoadjuvant chemotherapy;
• Patients with liver metastatic colorectal cancer who have achieved R0 resection according to MDT evaluation (including patients with metastases treated with ablation therapy that achieved similar R0 resection effects);
• Patients with negative ctDNA after surgery;
• ASA grade <IV and/or ECOG performance status score ≤ 2;
• Have sufficient understanding of the study and voluntarily sign an informed consent form.